Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013;3(3):552–74. https://doi.org/10.3390/metabo3030552.
Scalbert A, Huybrechts I, Gunter MJ. The food exposome. In: Dagnino S, Macherone A, editors. Unraveling the exposome: Springer International Publishing. 2019. p. 217–45. https://doi.org/10.1007/978-3-319-89321-1_8.
Rappaport SM, Barupal DK, Wishart D, Vineis P, Scalbert A. The blood exposome and its role in discovering causes of disease. Environ Health Perspect. 2014;122(8):769–74. https://doi.org/10.1289/ehp.1308015.
González-Domínguez R, Jáuregui O, Queipo-Ortuño MI, Andrés-Lacueva C. Characterization of the human exposome by a comprehensive and quantitative large-scale multianalyte metabolomics platform. Anal Chem. 2020;92(20):13767–75. https://doi.org/10.1021/acs.analchem.0c02008.
Gonzalez-Franquesa A, Burkart AM, Isganaitis E, Patti ME. What have metabolomics approaches taught us about type 2 diabetes? Curr Diab Rep. 2016;16(8):74. https://doi.org/10.1007/s11892-016-0763-1.
Ahola-Olli AV, Mustelin L, Kalimeri M, et al. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts. Diabetologia. 2019;62(12):2298–309. https://doi.org/10.1007/s00125-019-05001-w.
Sun Y, Gao HY, Fan ZY, He Y, Yan YX. Metabolomics signatures in type 2 diabetes: a systematic review and integrative analysis. J Clin Endocrinol Metab. 2020;105(4):1000–8. https://doi.org/10.1210/clinem/dgz240.
McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular metabolomics. Circ Res. 2018;122(9):1238–58. https://doi.org/10.1161/CIRCRESAHA.117.311002.
Cavus E, Karakas M, Ojeda FM, et al. Association of circulating metabolites with risk of coronary heart disease in a European population: results from the biomarkers for cardiovascular risk assessment in Europe (BiomarCaRE) Consortium. JAMA Cardiol. 2019;4(12):1270–9. https://doi.org/10.1001/jamacardio.2019.4130.
Müller J, Bertsch T, Volke J, et al. Narrative review of metabolomics in cardiovascular disease. J Thorac Dis. 2021;13(4):2532–50. https://doi.org/10.21037/jtd-21-22.
His M, Viallon V, Dossus L, et al. Prospective analysis of circulating metabolites and breast cancer in EPIC. BMC Med. 2019;17(1):178. https://doi.org/10.1186/s12916-019-1408-4.
Schmidt JA, Fensom GK, Rinaldi S, et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition. BMC Med. 2017;15(1):122. https://doi.org/10.1186/s12916-017-0885-6.
Schmidt JA, Fensom GK, Rinaldi S, et al. Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: a prospective study of 3,057 matched case-control sets from EPIC. Int J Cancer. 2020;146(3):720–30. https://doi.org/10.1002/ijc.32314.
Dossus L, Kouloura E, Biessy C, et al. Prospective analysis of circulating metabolites and endometrial cancer risk. Gynecologic Oncol. 2021. https://doi.org/10.1016/j.ygyno.2021.06.001.
Guida F, Tan VY, Corbin LJ, et al. The blood metabolome of incident kidney cancer: a case–control study nested within the MetKid consortium. PLOS Med. 2021;18(9):e1003786. https://doi.org/10.1371/journal.pmed.1003786.
Shu X, Xiang YB, Rothman N, et al. Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer. 2018;143(3):527–34. https://doi.org/10.1002/ijc.31341.
Harlid S, Gunter MJ, Van Guelpen B. Risk-predictive and diagnostic biomarkers for colorectal cancer; a systematic review of studies using pre-diagnostic blood samples collected in prospective cohorts and screening settings. Cancers. 2021;13(17):4406. https://doi.org/10.3390/cancers13174406.
Rothwell JA, Bešević J, Dimou N, et al. Circulating amino acid levels and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition and UK Biobank cohorts (In preparation).
Stepien M, Duarte-Salles T, Fedirko V, et al. Alteration of amino acid and biogenic amine metabolism in hepatobiliary cancers: findings from a prospective cohort study. Int J Cancer. 2016;138(2):348–60. https://doi.org/10.1002/ijc.29718.
Shu X, Zheng W, Yu D, et al. Prospective metabolomics study identifies potential novel blood metabolites associated with pancreatic cancer risk. Int J Cancer. 2018;143(9):2161–7. https://doi.org/10.1002/ijc.31574.
Zeleznik OA, Clish CB, Kraft P, Avila-Pacheco J, Eliassen AH, Tworoger SS. Circulating lysophosphatidylcholines, phosphatidylcholines, ceramides, and sphingomyelins and ovarian cancer risk: a 23-year prospective study. J Natl Cancer Inst. 2020;112(6):628–36. https://doi.org/10.1093/jnci/djz195.
Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, inflammation, and cancer. Annu Rev Pathol. 2016;11:421–49. https://doi.org/10.1146/annurev-pathol-012615-044359.
Wiebe N, Stenvinkel P, Tonelli M. Associations of chronic inflammation, insulin resistance, and severe obesity with mortality, myocardial infarction, cancer, and chronic pulmonary disease. JAMA Netw Open. 2019;2(8):e1910456. https://doi.org/10.1001/jamanetworkopen.2019.10456.
Li Y, Schoufour J, Wang DD, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ. 2020:l6669. https://doi.org/10.1136/bmj.l6669.
Pietzner M, Stewart ID, Raffler J, et al. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med. 2021:1–9. https://doi.org/10.1038/s41591-021-01266-0.
Kühn T, Floegel A, Sookthai D, et al. Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Med. 2016;14:13. https://doi.org/10.1186/s12916-016-0552-3.
Gross SM, Tibshirani R. Data shared lasso: a novel tool to discover uplift. Comput Stat Data Anal. 2016;101:226–35. https://doi.org/10.1016/j.csda.2016.02.015.
Ollier E, Viallon V. Regression modelling on stratified data with the lasso. Biometrika. 2017;104(1):83–96. https://doi.org/10.1093/biomet/asw065.
Ballout N, Garcia C, Viallon V. Sparse estimation for case-control studies with multiple disease subtypes. Biostatistics. 2021;22(4):738–55. https://doi.org/10.1093/biostatistics/kxz063.
Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113–24. https://doi.org/10.1079/PHN2002394.
Viallon V, His M, Rinaldi S, et al. A new pipeline for the normalization and pooling of metabolomics data. Metabolites. 2021;11(9):631. https://doi.org/10.3390/metabo11090631.
Chavent M, Kuentz-Simonet V, Liquet B, Saracco J. ClustOfVar: an R package for the clustering of variables. J Stat Software. 2012;50:1–16. https://doi.org/10.18637/jss.v050.i13.
Carayol M, Leitzmann MF, Ferrari P, et al. Blood metabolic signatures of body mass index: a targeted metabolomics study in the EPIC cohort. J Proteome Res. 2017;16(9):3137–46. https://doi.org/10.1021/acs.jproteome.6b01062.
Kliemann N, Viallon V, Murphy N, et al. Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition. BMC Med. 2021;19(1):101. https://doi.org/10.1186/s12916-021-01970-1.
Pischon T, Nimptsch K. Obesity and cancer. Recent Results in Cancer Research. Cham: Springer; 2016. https://doi.org/10.1007/978-3-319-42542-9.
Fortner RT, Katzke V, Kühn T, Kaaks R. Obesity and breast cancer. Recent Results Cancer Res. 2016;208:43–65. https://doi.org/10.1007/978-3-319-42542-9_3.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–32. https://doi.org/10.1038/s41575-019-0189-8.
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84. https://doi.org/10.1016/j.eururo.2018.08.036.
Dashti SG, English DR, Simpson JA, et al. Adiposity and endometrial cancer risk in postmenopausal women: a sequential causal mediation analysis. Cancer Epidemiol Biomarkers Prev. 2021;30(1):104–13. https://doi.org/10.1158/1055-9965.EPI-20-0965.
Tibshirani R. Regression shrinkage and selection via the lasso. J Royl Stat Soc Series B (Methodological). 1996;58(1):267–88. https://doi.org/10.1111/j.2517-6161.1996.tb02080.x.
Zou H. The adaptive lasso and its oracle properties. J Am Stat Assoc. 2006;101(476):1418–29. https://doi.org/10.1198/016214506000000735.
Krämer N, Schäfer J, Boulesteix AL. Regularized estimation of large-scale gene association networks using graphical Gaussian models. BMC Bioinformatics. 2009;10(1):384. https://doi.org/10.1186/1471-2105-10-384.
He K, Wang Y, Zhou X, Xu H, Huang C. An improved variable selection procedure for adaptive Lasso in high-dimensional survival analysis. Lifetime Data Anal. 2019;25(3):569–85. https://doi.org/10.1007/s10985-018-9455-2.
Ballout N, Etievant L, Viallon V. On the use of cross-validation for the calibration of the adaptive lasso. arXiv. 2005:10119 Published online July 15, 2021. Accessed 1 Dec 2021. http://arxiv.org/abs/2005.10119.
Chen Y, Yang Y. The one standard error rule for model selection: does it work? Stats. 2021;4(4):868–92. https://doi.org/10.3390/stats4040051.
Bach FR. Bolasso: model consistent Lasso estimation through the bootstrap. In: Proceedings of the 25th International Conference on Machine Learning. ICML ’08: Association for Computing Machinery. 2008. p. 33–40. https://doi.org/10.1145/1390156.1390161.
Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Stat. 2004;32(2):407–99. https://doi.org/10.1214/009053604000000067.
Taylor J, Tibshirani R. Post-selection inference for -penalized likelihood models. Can J Stat. 2018;46(1):41–61. https://doi.org/10.1002/cjs.11313.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royl Stat Soc Series B (Methodological). 1995;57(1):289–300.
Treede I, Braun A, Sparla R, et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem. 2007;282(37):27155–64. https://doi.org/10.1074/jbc.M704408200.
Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–50. https://doi.org/10.1038/nrm2329.
Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5:e189. https://doi.org/10.1038/oncsis.2015.49.
Klein MS, Shearer J. Metabolomics and type 2 diabetes: translating basic research into clinical application. J Diabetes Res. 2016;2016:3898502. https://doi.org/10.1155/2016/3898502.
Stepien M, Keski-Rahkonen P, Kiss A, et al. Metabolic perturbations prior to hepatocellular carcinoma diagnosis: findings from a prospective observational cohort study. Int J Cancer. 2021;148(3):609–25. https://doi.org/10.1002/ijc.33236.
Newton H, Wang YF, Camplese L, et al. Systemic muscle wasting and coordinated tumour response drive tumourigenesis. Nat Commun. 2020;11:4653. https://doi.org/10.1038/s41467-020-18502-9.
Gumpenberger T, Brezina S, Keski-Rahkonen P, et al. Untargeted metabolomics reveals major differences in the plasma metabolome between colorectal cancer and colorectal adenomas. Metabolites. 2021;11(2):119. https://doi.org/10.3390/metabo11020119.
Elia I, Broekaert D, Christen S, et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 2017;8(1):15267. https://doi.org/10.1038/ncomms15267.
Watford M. Glutamine metabolism and function in relation to proline synthesis and the safety of glutamine and proline supplementation. J Nutr. 2008;138(10):2003S–7S. https://doi.org/10.1093/jn/138.10.2003S.
Lécuyer L, Dalle C, Lyan B, et al. Plasma metabolomic signatures associated with long-term breast cancer risk in the SU.VI.MAX prospective cohort. Cancer Epidemiol Biomarkers Prev. 2019;28(8):1300–7. https://doi.org/10.1158/1055-9965.EPI-19-0154.
Jobard E, Dossus L, Baglietto L, et al. Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort. Br J Cancer. 2021;124(10):1734–43. https://doi.org/10.1038/s41416-021-01304-1.
Fages A, Duarte-Salles T, Stepien M, et al. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med. 2015;13:242. https://doi.org/10.1186/s12916-015-0462-9.
Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Analytica Chimica Acta. 2008;624(2):269–77. https://doi.org/10.1016/j.aca.2008.06.051.
Plewa S, Horała A, Dereziński P, et al. Usefulness of amino acid profiling in ovarian cancer screening with special emphasis on their role in cancerogenesis. Int J Mol Sci. 2017;18(12):E2727. https://doi.org/10.3390/ijms18122727.
Yi H, Talmon G, Wang J. Glutamate in cancers: from metabolism to signaling. J Biomed Res. 2019;34(4):260–70. https://doi.org/10.7555/JBR.34.20190037.
Plewa S, Horała A, Dereziński P, Nowak-Markwitz E, Matysiak J, Kokot ZJ. Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers. Life Sci. 2019;222:235–44. https://doi.org/10.1016/j.lfs.2019.03.004.
Wu G, Bazer FW, Davis TA, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37(1):153–68. https://doi.org/10.1007/s00726-008-0210-y.
Papadimitriou N, Gunter MJ, Murphy N, et al. Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies. Int J Cancer. 2021;149(9):1659–69. https://doi.org/10.1002/ijc.33725.
Muñoz-Esparza NC, Latorre-Moratalla ML, Comas-Basté O, Toro-Funes N, Veciana-Nogués MT, Vidal-Carou MC. Polyamines in food. Front Nutr. 2019;6:108. https://doi.org/10.3389/fnut.2019.00108.
Moinard C, Cynober L, de Bandt JP. Polyamines: metabolism and implications in human diseases. Clin Nutr. 2005;24(2):184–97. https://doi.org/10.1016/j.clnu.2004.11.001.
Vargas AJ, Ashbeck EL, Wertheim BC, et al. Dietary polyamine intake and colorectal cancer risk in postmenopausal women. Am J Clin Nutr. 2015;102(2):411–9. https://doi.org/10.3945/ajcn.114.103895.
Pietrocola F, Castoldi F, Kepp O, Carmona-Gutierrez D, Madeo F, Kroemer G. Spermidine reduces cancer-related mortality in humans. Autophagy. 2018;15(2):362–5. https://doi.org/10.1080/15548627.2018.1539592.
Fan J, Feng Z, Chen N. Spermidine as a target for cancer therapy. Pharmacol Res. 2020;159:104943. https://doi.org/10.1016/j.phrs.2020.104943.
Koelmel JP, Ulmer CZ, Jones CM, Yost RA, Bowden JA. Common cases of improper lipid annotation using high-resolution tandem mass spectrometry data and corresponding limitations in biological interpretation. Biochim Biophys Acta. 2017;1862(8):766–70. https://doi.org/10.1016/j.bbalip.2017.02.016.
Köfeler HC, Ahrends R, Baker ES, et al. Recommendations for good practice in MS-based lipidomics. J Lipid Res. 2021;62:100138. https://doi.org/10.1016/j.jlr.2021.100138.
Floegel A, Drogan D, Wang-Sattler R, et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS One. 2011;6(6):e21103. https://doi.org/10.1371/journal.pone.0021103.
Townsend MK, Clish CB, Kraft P, et al. Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. Clin Chem. 2013;59(11):1657–67. https://doi.org/10.1373/clinchem.2012.199133.
Carayol M, Licaj I, Achaintre D, et al. Reliability of serum metabolites over a two-year period: a targeted metabolomic approach in fasting and non-fasting samples from EPIC. PLoS One. 2015;10(8):e0135437. https://doi.org/10.1371/journal.pone.0135437.
